Varenicline to stop long-term nicotine replacement use: A double-blind, randomized, placebo-controlled trial

Nicotine and Tobacco Research

Volumn 15, Issue 2, 2013, Pages 419-427

  Tønnesen, Philip ^a   Mikkelsen, Kim ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; COTININE; NICOTINE; NICOTINE GUM; NICOTINE LOZENGE; PLACEBO; VARENICLINE;

ABNORMAL DREAMING; ADULT; ARTICLE; BODY WEIGHT; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CONSTIPATION; CONTROLLED STUDY; DENGUE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXPIRED AIR; FEMALE; HEART ARREST; HIP CIRCUMFERENCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; VOMITING; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WITHDRAWAL SYNDROME;

BENZAZEPINES; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC ANTAGONISTS; PLACEBOS; QUESTIONNAIRES; QUINOXALINES; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84872871120     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/nts146     Document Type: Article

References (35)

1. Agrawal, A., Scherrer, S. F., Pergadia, M. L., Lynskey, M. T., Madden, P. A., Sartor, C. E., Xian, H. (2011) A latent class analysis of DSM-IV and Fagerström (FTND) criteria for nicotine dependence. Nicotine & Tobacco Research, 13, 972-981. doi:10.1093/ntr/ntr105.
2. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR). Diagnostic Code 292.0. Washington DC: Author. Retrieved from http://www.psych.org/MainMenu/Research/DSMIV/DSMIVTR.aspx.
3. Assali, A. R., Beigel, Y., Schreibman, R., Shafer, Z., & Fainaru, M. (1999). Weight gain and insulin resistance during nicotine replacement therapy. Clinical Cardiology, 22, 357-360. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/clc.4960220512/pdf.
4. Benowitz, N. L. (1990). Clinical pharmacology of inhaled drugs of abuse: Implications in understanding nicotine dependence. In C. N. Chiang & R. L. Hawks (Eds.), Research findings on smoking of abused substances. National Institute on Drug Abuse Research Monograph 99 (12-29.28). Rockville, MD: U.S. Department of Health and Human Services, Public Health Service. Retrieved from http://archives.drugabuse.gov/pdf/monographs/99.pdf#page=19.
5. Benowitz, N. L., Prochet, H., Sheiner, L., & Jacob, P. (1988). Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gum. Clinical Pharmacology and Therapeutics, 44, 23-28. doi:10.1038/clpt.1988.107.
6. Cahill, K., Stead, L. F., & Lancaster, T. (2007). Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, (1), CD006103. doi:10.1002/14651858. CD006103.pub2. Retrieved from http://www.update-software.com/BCP/WileyPDF/EN/CD006103.pdf.
7. Czernichow, S., Kengne, A. P., Stamatakis, E., Hamer, M., & Batty, G. D. (2011). Body mass index, waist circumference and waist-hip ratio: Which is the better discriminator of cardiovascular disease mortality risk? Evidence from an individual-participant metaanalysis of 82,864 participants from nine cohort studies. Obesity Review, 12, 680-687. doi:10.1111/j.1467-789X.2011.00879.
8. Doherty, K., Kinnunen, T., Militello, F. S., & Garvey, A. J. (1995). Urges to smoke during the first month of abstinence: Relationship to relapse and predictors. Psychopharmacology, 119, 171-178. doi:10.1007/BF02246158.
9. Eliasson, B., & Smith, U. (1999). Leptin levels in smokers and long-term users of nicotine gum. European Journal of Clinical Investigation, 29, 145-152. doi:10.1046/j.1365-2362.1999.00420.
10. Eliasson, B., Taskinen, M. R., & Smith, U. (1996). Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation, 94, 878-881. doi:10.1161/01. CIR.94.5.878.
11. Etter, J.-F. (2009). Dependence on the nicotine gum in former smokers. Addictive Behaviors, 34, 246-251. doi:10.1186/1471-2458-7-159.
12. Fagerström, K., Gilljam, H., Metcalfe, M., Tonstad, S., & Messig, M. (2010). Stopping smokeless tobacco with varenicline: Randomized double blind placebo controlled trial. British Medical Journal, 341, 6549-6557. doi:10.1136/bmj.c6549.
13. Fant, R. V., Henningfield, J. E., Shiffman, S., Strahs, K. R., & Reitberg, D. P. (2000). A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacology Biochemistry and Behavior, 67, 479-82. doi:10.1016/S0091-3057(00)00399-3.
14. Fiore, M. C., Bailey, W. C., Cohen, S. J., Dorfman, S. F., Goldstein, M. F., Gritz, E. R., Wewers, M.E. (2008). Treating tobacco use and dependence. Clinical practice guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service. Retrieved from http://www.ahrq/clinic/tobacco/treating_ tobacco_use08.pdf.
15. Ford, C. L., & Zlabek, J. A. (2005). Nicotine replacement therapy and cardiovascular disease. Mayo Clinic Proceedings, 80, 651-656. doi:10.4065/80.5.652.
16. Gonzales, D., Rennard, S. I., Nides, M., Azoulays, S., Billing, C. B., Watsky, E. J., Reeves, K. R. (2006). Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustainedrelease bupropion and placebo for smoking cessation. Journal of the American Medical Association, 296, 47-55. doi:10.1001/jama.296.1.47.
17. Gorsline, J. (1993). Nicotine pharmacokinetics of four nicotine transdermal systems. Health Values, 17, 20-24. Retrieved from http://www.cctc.ca/cctc/EN/tcrc/articles/tcarticle.2010-08-23.4307030237.
18. Hajek, P., Jackson, P., & Belcher, M. (1988). Long-term use of nicotine chewing gum. Occurrence, determinants, and effect on weight gain. Journal of the American Medical Association, 260, 1593-1596. Retrieved from http://archinte.ama-assn.org/cgi/citmgr?gca=archinte;151/10/1993.
19. Hajek, P., McRobbie, H., & Gillison, F. (2007). Dependence potential of nicotine replacement treatments: Effects of product type, patient characteristics, and cost to user. Preventive Medicine, 44, 230-234. doi:10.1016/j.ypmed.2006.10.005.
20. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127. doi:10.1186/1471-2458-9-493.
21. Henningfield, J. E., & Keenan, R. M. (1993). Nicotine delivery kinetics and abuse liability. Journal of Consulting and Clinical Psychology, 61, 743-750. doi:10.1037/0022-006X.61.5.743.
22. Hurt, R. D., Offord, K. P., Lauger, G. G., Marusić, Z., Fagerström, K. O., Enright, P. L., & Scanlon, P. D. (1995). Cessation of long-term nicotine gum use - a prospective, randomized trial. Addiction, 90, 407-413. doi:10.1046/j.1360-0443.1995. 9034079.
23. Hughes, J. R., Gust, S. W., Keenan, R., Fenwick, J. W., Skoog, K., & Higgins, S. T. (1991). Long-term use of nicotine vs. placebo gum. Archives of Internal Medicine, 151, 1993-1998. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed?term=Hughes.
24. Jarvis, M. J., Russell, M. A., & Saloojee, Y. (1980). Expired air carbon monoxide: A simple breath test of tobacco smoke intake. British Medical Journal, 281, 484-485. doi:10.1136/bmj.281.6238.484.
25. 2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation. Journal of the American Medical Association, 296, 56-63. doi:10.1001/jama.296.1.56.
26. Killen, J. D., & Fortmann, S. P. (1997). Craving is associated with smoking relapse: Findings from three prospective studies. Experimental and Clinical Psychopharmacology, 5, 137-142. doi:10.1037/1064-1297.5.2.137.
27. Murray, R. P., Nides, M. A., Istvan, J. A., & Daniels, K. (1998). Levels of cotinine associated with long-term ad-libitum nicotine polacrilex use in a clinical trial. Addictive Behaviors, 23, 529-535. doi:10.1016/S0306-4603(97)00073-7.
28. Nemeth-Coslett, R., Henningfield, J. E., O'Keefe, M. K., & Griffiths, R. R. (1987). Nicotine gum: Dose-related effects on cigarette smoking and subjective ratings. Psychopharmacology, 92, 424-430. doi:10.1007/BF00176472.
29. Seersholm, N., Nielsen, N. H., & Tonnesen, P. (1999). Selfreported smoking habits, biochemical markers, and nicotine dependence in a sample of the Danish population. Journal of the Royal Society for Promotion of Health, 119, 92-96. doi:10.1177/146642409911900206.
30. Shiffman, S., Hughes, J. R., Pillitteri, J. L., & Burton, S. L. (2003). Persistent use of nicotine replacement therapy: An analysis of actual purchase patterns in a population based sample. Tobacco Control, 12, 310-316. doi:10.1136/tc.12.3.310.
31. Shiffman, S., West, R. J., & Gilbert, D. G. (2004). Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine & Tobacco Research, 6, 599-614. doi:10.1080/14622200410001734067.
32. Stitzer, M. L. & De Wit, H. (1998). Abuse liability of nicotine. In N. L. Benowitz (Ed.), Nicotine safety and toxicity (pp. 119-131). New York: Oxford University Press. Retrieved from http://tobaccodocuments.org/product_design/515707730-7876.html.
33. Tonstad, S., Tønnesen, P., Hajek, P., Williams, K. E., Billing, C. B., & Reeves, K. R. (2006). Effect of maintenance therapy with varenicline on smoking cessation. Journal of the American Medical Association, 296, 64-67. doi:10.1001/jama. 296.1.64.
34. West, R. J., Hajek, P., & Belcher, M. (1989). Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychological Medicine, 19, 981-985. doi:10.1017/S0033291700005705.
35. West, R. J. & Russell, M. A. (1985). Effects of withdrawal from long-term nicotine gum use. Psychological Medicine, 15, 891-893. doi:10.1017/S0033291700005134.